Ocean Biotech redeems 20 million yuan of idle raised funds for financial management, earning 4,662,000 yuan in returns and continuing to invest an additional 10 million yuan.

MaticHoleFiller · 2026-04-10T00:59:42+00:00

Ocean Biological recently announced the progress of cash management for fundraising, with its subsidiary Fujian Shunyue redeeming 20 million yuan worth of financial products, realizing a profit of 466.2k yuan, and continuing to reinvest 10 million yuan in large-denomination certificates of deposit. The company ensures that the use of funds does not affect the fundraising projects and has taken measures to control investment risks.

MaticHoleFiller

2026-04-10 00:59:42

Abstract generation in progress

Zhejiang Dayang Biotechnology Group Co., Ltd. (Stock code: 003017,简称 “Dayang Biotech”) recently issued an announcement disclosing the progress of redeeming and reinvesting part of the idle raised funds for cash management. The company’s subsidiary Fujian Shunyue Technology Co., Ltd. (简称 “Fujian Shunyue”) redeemed two wealth management products totaling 20 million yuan, earning a total profit of 466.2k yuan, and on the same day, continued to invest 10 million yuan in large-denomination certificates of deposit issued by Hangzhou Bank.

Idle raised funds for wealth management matured and redeemed, with investment returns exceeding 460k yuan

The announcement shows that Fujian Shunyue previously purchased two large-denomination certificates of deposit wealth management products from Hangzhou Bank on April 18 and April 29, 2025, each with a value of 10 million yuan. On March 30, 2026, these two wealth management products matured and were redeemed, with the principal of 20 million yuan fully recovered, and earnings of 232.2k yuan and 234k yuan respectively, totaling 466.2k yuan. The principal and earnings from the redemption have been fully deposited into the dedicated account for raised funds.

No.	Subscription Amount	Bank	Subscription Entity	Product Name	Product Type	Expected Annualized Return	Investment Income	Start Date	Maturity Date
1	10M	Hangzhou Bank	Fujian Shunyue	Large-Denomination Certificate of Deposit Multi-Service G29 3-Year	Principal-protected Floating Yield	2.45%	232,200	September 27, 2024	September 27, 2027
2	10M	Hangzhou Bank	Fujian Shunyue	Large-Denomination Certificate of Deposit Multi-Service G31 2-Year	Principal-protected Floating Yield	2.55%	234,000	August 20, 2024	August 20, 2026

Continued investment of 10 million yuan in principal-protected wealth management with a 3-year term

On the same day as redeeming the above wealth management products, Fujian Shunyue used 10 million yuan of idle raised funds to purchase a new large-denomination certificate of deposit wealth management product from Hangzhou Bank. The product is named “Large-Denomination Certificate of Deposit G008 3-Year,” which is principal-protected with floating yield, with an expected annualized return of 2.30%, starting from January 26, 2025, and maturing on January 26, 2028.

No.	Subscription Entity	Signing Bank	Product Name	Product Type	Subscription Amount	Start Date	Maturity Date	Expected Annualized Return
1	Fujian Shunyue	Hangzhou Bank	Large-Denomination Certificate of Deposit G008 3-Year	Principal-protected Floating Yield	10M	January 26, 2025	January 26, 2028	2.30%

Cash management does not affect fundraising projects; total unexpired amount is 90 million yuan

Dayang Biotech states that this cash management of idle raised funds is carried out under the premise of ensuring the normal use of funds needed for the company’s fundraising projects. It will not affect the construction of the company’s fundraising projects and can effectively improve the efficiency of fund utilization, providing better investment returns for the company and shareholders.

The announcement also discloses that as of the date of this announcement, the amount of idle raised funds used for cash management by the company and its subsidiaries that has not yet matured is 90 million yuan, which does not exceed the authorized limit of 120 million yuan approved at the fifth meeting of the sixth board of directors (with rolling use allowed).

Risk control measures to ensure fund safety

The company points out that all purchased investment products have undergone strict evaluation and screening, but returns may still be affected by macroeconomic and market fluctuations. To control risks, the company will select products issued by reputable, large-scale institutions with strong capital operation capabilities, with good liquidity and short terms. The company will also track and analyze the investment direction and project progress of the products in a timely manner, and take protective measures if adverse factors are found. Independent directors and the supervisory committee have the right to supervise and inspect the use of funds, and may hire professional agencies for audits if necessary.

Dayang Biotech states that the company will continue to fulfill its information disclosure obligations in accordance with relevant regulations of the Shenzhen Stock Exchange.

Click to view the original announcement>>

Disclaimer: The market carries risks; investments should be cautious. This article is automatically published by an AI large model based on third-party databases and does not represent Sina Finance’s views. All information in this article is for reference only and does not constitute personal investment advice. Please refer to the actual announcement for any discrepancies. If you have questions, contact biz@staff.sina.com.cn.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.